Brad Loncar
Entrepreneur, investor w/ a #biotech focus, avid reader, KC native, alumnus of @univmiami. 👻: bradloncar
Last synced from Twitter 1m ago
The Bold New Player in Cancer: How Chinese Biotechs Are Fueling the Oncology Space
Brad Loncar
For those in the biotech industry who are interested in learning about how to do business development in China, my friend James Lee and I are hosting a webinar with BeiGene and I-Mab BD chiefs on Monday, December 2nd. portal.emailnetworks.com/vm2/7045834e97… pic.twitter.com/Cse3lMqJ4y
3d
Detecting Pancreatic Cancer Early Is Crucial
Why early detection of pancreatic cancer is so important.
'Liberal arts' and coding as a 'second language': How hiring is changing for banks in Asia
Banks in Asia and the Middle East are gearing their hiring plans toward creative minds as they look to embrace the digital age, according to a panel of top executives.
U.S. FDA Grants BeiGene’s BRUKINSA™ (zanubrutinib) Accelerated Approval to Treat Adult Patients with Mantle Cell Lymphoma Who Received at Least One Prior Therapy
1
Brad Loncar
An innovative drug by a Chinese company is approved by FDA. This PDUFA wasn’t until late February. Congrats BeiGene! 🎉
8d
【独家】百济神州PD-1替雷利珠单抗结束技术审评，正式获批在即|界面新闻
替雷利珠单抗将成为国内第6款获批的PD-1，同时也是第4个获批的国产PD-1产品。
China’s Drug Market Is Opening Up
China’s plan to make its health-care system better and more affordable is throwing up opportunities for global drugmakers.
Ash 2019 preview – the first winner and losers emerge
Celgene’s registrational Transcend NHL-001 study will be a big story at Ash, but the early focus falls on what has not been presented.
4
Brad Loncar
I asked the expert @JacobPlieth what he is watching for at #ASH19. Here’s a link to his full preview: evaluate.com/vantage/articl… pic.twitter.com/Uu7QfPw4sO
14d
Hua Medicine to Release Phase III 24-Weeks Topline Data of Dorzagliatin Monotherapy Trial (HMM0301) on November 12-Hua Medicine
Brad Loncar
Hua Medicine says it will release P3 24-week topline Dorzagliatin monotherapy data Monday AM.
This is newsworthy because Hua was the second company to IPO in HK last year and this is potentially the first true binary-type trial readout of a HK company.
14d
NASH biotech 89bio postpones $70 million IPO
89bio, a Phase 1 biotech developing therapies for NASH and other metabolic diseases, postponed its IPO on Wednesday.
WSJ News Exclusive | AstraZeneca to Raise $1 Billion to Invest in China Startups
AstraZeneca plans to raise up to $1 billion for a fund that would invest in China’s health-care startups, the latest drug giant to bet on the fast-growing pharmaceuticals market.
Seattle Genetics Responds to Daiichi Sankyo’s Complaint for Declaratory Judgment
Seattle Genetics, Inc. (Nasdaq:SGEN) today released the following statement in response to Daiichi Sankyo’s filing of a Declaratory Judgment action alleging Seattle Genetics is not entitled to intellectual property rights under a collaboration...
A New Approach to Gene Therapy—Now In Dogs, Maybe Later In Humans
Gene therapy has successfully been used to treat age-related ailments in mice. Now it’s being studied in dogs.
Studies Yield ‘Impressive’ Results in Fight Against Cystic Fibrosis
The findings hold promise for a vast majority of those with cystic fibrosis, according to the director of the National Institutes of Health. “This should be a cause for major celebration,” he wrote.
Healthcare Earnings for the Week of May 6
1
Brad Loncar
This is the busiest week of earnings ahead. Too many companies to mention. The full schedule here: loncarblog.com/november-4-ear… pic.twitter.com/k6NkULNNAl
19d
Facebook, Restaurant Brands, PG&E: Stocks That Defined the Week
While the S&P 500 and Nasdaq Composite Index hit records this week, here are seven stocks that moved on the week’s business news.
Brad Loncar
BeiGene should have made this list. If biotech wasn’t the Rodney Dangerfield of the stock market.
19d
刚刚！GV-971获批！
刚刚，全球首个国产糖类多靶抗阿尔兹海默病创新药GV-971获批。\x26gt;\x26gt;\x26gt;
Brad Loncar
China NMPA approved an Alzheimer’s drug today, GV-971. Thought I’d share b/c it’s a big topic on China equivalent to biotwitter currently (yes, that exists).
20d